MedTrace Logo

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions

NCT00881426 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-03-29

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Cefzil 500 mg Cefprozil tablets under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Cefprozil 500 mg Tablets (Sandoz GmbH)

DRUG

Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)

Sponsors & Collaborators

Principal Investigators

  • Gaetano Morelli, M.D. · MDS Pharma Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2004-04-30
Completion
2004-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881426 on ClinicalTrials.gov